| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.06 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.056 | 0.06 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.06 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.055 | 0.06 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.06 | 0.06 |